Chromane HDAC Inhibitors Isoform Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HDAC inhibitors are largely pan-inhibitors with adverse side effects, necessitating the development of isoform-selective HDAC inhibitors for improved therapeutic efficacy and reduced side effects.
Innovation Solution
Development of chromane compounds that demonstrate selective HDAC inhibition, specifically targeting histone deacetylases (HDACs) with a structure represented by Formula (II) and its derivatives, which can be used to inhibit histone acetylation in cells and treat malignancies and infectious diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pan-HDAC inhibitors are used to inhibit histone deacetylases, then HDAC inhibition activity is achieved, but adverse side effects occur due to lack of selectivity
Solution Approach 1:
The patent applies local quality by designing HDAC inhibitors with specific structural modifications at particular regions of the molecule. The compounds feature a cap group, hydroxamic acid moiety, and linker with specific substitutions (such as fluorine atoms at positions 2 and 6 of the phenyl ring) that confer selectivity for specific HDAC isoforms while maintaining inhibition activity. This localized structural optimization allows the inhibitor to selectively bind to target HDAC enzymes without affecting other isoforms, thereby reducing adverse side effects associated with pan-HDAC inhibition.
2Object-affected harmful factors
If isoform-selective HDAC inhibitors are developed to reduce side effects, then therapeutic efficacy is improved, but compound structure complexity increases
Solution Approach 1:
The patent employs segmentation by dividing the HDAC inhibitor molecule into distinct functional segments: a cap group (such as phenyl or heteroaryl rings), a linker (such as piperazine or piperidine rings), and a hydroxamic acid moiety. Each segment can be independently optimized for specific functions—the cap group provides selectivity through specific substitutions (like fluorine atoms), the linker provides structural flexibility and binding orientation, and the hydroxamic acid provides zinc chelation. This modular segmentation allows for systematic structure-activity relationship optimization without requiring complete redesign of the entire molecule.
Solution Approach 2:
The patent applies parameter changes by systematically varying specific molecular parameters such as the type of substituents on the cap group (fluorine, chlorine, methyl), the length and composition of the linker, and the stereochemistry of chiral centers. These parameter modifications allow fine-tuning of the inhibitor's selectivity profile for different HDAC isoforms while maintaining acceptable structural complexity. For example, changing from unsubstituted phenyl to 2,6-difluorophenyl provides enhanced selectivity without dramatically increasing molecular weight or complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chromane compounds effectively inhibit histone acetylation, offering a potential for better therapeutic outcomes with reduced side effects by selectively targeting specific HDAC isoforms, thus addressing the limitations of existing HDAC inhibitors.
Implementation Method 1
HDAC inhibitors have great potential for the therapy of human cancers. The chromane compounds effectively inhibit histone acetylation, offering a potential for better therapeutic outcomes with reduced side effects by selectively targeting specific HDAC isoforms
Data Source
AI summary
The present disclosure is directed to chromane compounds, chromane compounds demonstrating HDAC inhibition, and pharmaceutical compositions thereof. Additional embodiments include methods of using the chromane compounds. For example, the disclosure includes methods of inhibiting histone acetylation in a cell, comprising contacting the cell with a chromane compound of the disclosure. Additional embodiments include methods of treating a disease capable of treatment by inhibition of histone acetylation in a patient in need thereof, comprising administering a chromane compound of the disclosure.